The prevalence of cardiometabolic risk factors and the ten-year risk of fatal cardiovascular events in patients with schizophrenia and related psychotic disorders

Psychiatria Danubina

Volumn 24, Issue 3, 2012, Pages 307-313

  Protopopova, Dita ^a   Masopust, Jiri ^a   Maly, Radovan ^a   Valis, Martin ^b   Bazant, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Cardiovascular; Mortality; Risk factor; Schizophrenia

Indexed keywords

GLUCOSE; LIPID;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PSYCHOSIS; RATING SCALE; RISK FACTOR; SCHIZOPHRENIA; SCORING SYSTEM; SMOKING HABIT; WAIST CIRCUMFERENCE;

ADULT; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; CZECH REPUBLIC; DYSLIPIDEMIAS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; PREVALENCE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; SMOKING;

EID: 84867791614     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Diabetes Association, American Psychiatric Association, American Association of clinical Endocrinologists, North American Association for the study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65: 267-72.
2. Bernando M, Canas F, Banegas JR, Casademont J, Riesgo Y & Varela C: On behalf of RICAVA Study Group. Prevalence and awarness of cardiovascular risk factors in patients with schizophrenia: A cross sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009; 24: 431-41.
3. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J on behalf of the CLAMORS Study Collaborative Group: Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophr Res 2007; 90: 162-173. (Pubitemid 46177553)
4. Bresee LC, Majumdar SR, Patten SB & Johnson JA: Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. Schizophr Res 2010; 117: 75-82.
5. Cifkova R, Skodova Z, Bruthansa J, Adamkova V, Jozifova M, Galovcova M, et al.: Longitudinal trends in major cardiovscular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010; 211: 676-81.
6. Cífková R, Býma S, Češka R, Horký K, Karen I, Kunešová M, et al.: Prevence Kardiovaskulárních onemocnění v dospě lém věku. Společné doporučení českých odborných společností. Supp Cor Vasa 2005; 47: 3-14.
7. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al.: SCORE project group. Estimation of ten- year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. (Pubitemid 36712275)
8. Daumit GL, Goff DC, Mezer JM, Davis VG, Nasrallah HA, McEvoy JP, et al.: Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE Schizophrenia study. Schizophr Res 2008; 105: 175-87.
9. De Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al.: Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
10. De Hert M, Dekker JM, Wood D, Kahl KG, Holt RIG &Moller H-J. Cardiovscular disease and diabetes in people with severe mental illness position statement from European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardilogy (ESC). Eur Psychiatry 2009; 24: 412-24.
11. De Hert M, Falissard B, Mauri M, Wetterling T, Doble A, Giudicelli A, et al.: Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study. Eur Neuropsychopharmacol 2008; 18: S444.
12. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol educational program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
13. Graham I, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, et al.: European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (Constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Supp 2): 10-40.
14. Kozumplik O, Uzun S, Jakovljević M: Metabolic syndrome in patients with psychotic disorders: diagnostic issues, comorbidity and side effects of antipsychotics. Psychiatr Danub 2010; 22: 69-74.
15. Leucht S, Burkard T, Henderson J, Maj M, Sartorius N: Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007; 116: 317-33. (Pubitemid 47537428)
16. Masopust J & Maly R: Prevence kardiovaskulárního rizika a diabetu u nemocných schizofrenií: využití internetu v praxi. Psychiatrie pro praxi 2010; 11: 130-4.
17. Melkersson K & Dahl M-L.: Adverse metabolic effects associated with atypical antipsychotics. Drugs 2004; 64: 701-23.
18. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Weiping Y, De Hert M: Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - A systematic review and meta-analysis. Schizophr Bull 2011 Dec 29. doi:10.1093/schbul/sbr148. [Ahead of Print].
19. Newcomer JW: Metabolic syndrome and mental illness. Am J Manag Care 2007; 13: S170-7.
20. Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin MR, Laurén LH, et al.: A 4-fold risk of metabolic syndrome in Patients with schizophrenia: a Northern Finland 1966 birth control study. J Clin Psychiatry 2005; 66: 559-63. (Pubitemid 40733696)
21. Svestka J, Synek O, Tomanova J, Rodaková I & Cejpkova A: Differences in the effect of second-generation antipsychotics on prolactinaemia: Six weeks open-label trial in female in-patients. Neuroendocrinol Lett 2007; 28:881-8.
22. Tiihonen J, Lonnquist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al.: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-7.
23. Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M: A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand 2011 Dec 19. doi: 10.1111/j.1600-0447.2011. 01814.x. [Ahead of Print].
24. Weinmann S, Read J & Aderhold V: Influence of antipsychotics on mortality in schizophrenia: Systematic review. Schizophr Res 2009; 113: 1-11.